pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzhei
Bagsværd, JP HQ
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
Placebo (ziltivekimab), ziltivekimab
Phase 3 · small molecule · Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Placebo (ziltivekimab), ziltivekimab for Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation is a Phase 3 program (small_molecule) at NovoThirteen with 1 ClinicalTrials.gov record(s).
Internal code EX6018-4758
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NovoThirteen
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
- Status
- active
- Trials
- 1